What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: Transient Ischemic Attack (TIA) (n=3981). Intervention: Implantable cardiac monitors vs. Non-invasive cardiac monitoring. Primary outcome: Newly detected AF of ≥30 seconds duration.

What does this research mean for the field?

Implantable cardiac monitors yield a significantly higher atrial fibrillation detection rate than non-invasive cardiac monitoring in patients following a transient ischemic attack. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To determine the rate of newly diagnosed atrial fibrillation (AF) using various ECG monitoring methods after transient ischemic attacks (TIAs).

May 8, 2026Open Access

Abstract Number: Esoc2026a1800 Cardiac Monitoring for Detection of Atrial Fibrillation After Tia: A Systematic Review and Meta-Analysis

Key Result

Implantable cardiac monitors yielded a significantly higher atrial fibrillation detection rate than non-invasive cardiac monitoring in TIA patients (20.8% vs. 4.7%).

Key Points

To determine the rate of newly diagnosed atrial fibrillation (AF) using various ECG monitoring methods after transient ischemic attacks (TIAs).
Systematic review and meta-analysis were conducted following PRISMA guidelines.
Literature search included studies from 1966 to May 31, 2025, with TIA patients monitored for >12 hours.
Primary outcome focused on newly detected AF of ≥30 seconds, analyzed by monitoring duration and method.
42 studies with 3,981 TIA patients were included, yielding a pooled AF detection rate of 6.5% (95% CI: 4.5–9.3%).
AF detection rates increased with monitoring duration: 3.5% (1 day), 6.3% (7 days), 9.6% (30 days), 13.1% (90 days), 19.1% (12 months).
Implantable cardiac monitors had a significantly higher AF detection rate (20.8%) compared to non-invasive methods (4.7%).

Study Design

Type

Meta-Analysis (n=3,981)

Structured PICO

Does prolonged or invasive cardiac monitoring improve the detection rate of newly diagnosed atrial fibrillation in patients following a TIA?

Population

3,981 patients with transient ischemic attack (TIA) from 42 studies (prospective observational and randomized controlled trials) who underwent >12 hours of cardiac monitoring.

Intervention

Various ECG monitoring methods, including implantable cardiac monitors and non-invasive cardiac monitoring (serial ECGs, 24-72h Holter, in-hospital telemetry), for durations ranging from >12 hours up to 12 months.

Comparator

Different monitoring methods (implantable vs. non-invasive) and durations (1 day, 7 days, 30 days, 90 days, 12 months), as well as selected vs. unselected patient cohorts.

Outcome

Newly detected atrial fibrillation (AF) of ≥30 seconds duration.

Prolonged and invasive cardiac monitoring, particularly with implantable devices, significantly increases the detection rate of atrial fibrillation in patients following a TIA.

Main Result

Absolute Event Rate: 20.8% vs 4.7%

Limitations

Substantial heterogeneity was observed among studies (I2 = 81.9%)

Abstract

Abstract Background and aims The optimal ECG monitoring method for sensitive detection of atrial fibrillation (AF) after TIAs is uncertain. This systematic review and meta-analysis aim to determine the rate of newly diagnosed AF using various ECG monitoring methods and durations after TIA. Methods A literature search from 1966 through May 31, 2025, was conducted in accordance with PRISMA guidelines using a protocol registered in PROSPERO (CRD420251075716). Prospective observational studies and randomized controlled trials were considered that included TIA patients who underwent 12 hours of cardiac monitoring. Primary outcome was newly detected AF of ≥30 seconds duration, with subgroup analyses by monitoring duration and method. Results 42 studies enrolling 3,981 TIA patients were included. The pooled AF detection rate was 6.5% (95% CI: 4.5–9.3%). Yield of monitoring was higher in in selected cohorts characterized by higher age, cryptogenic stroke etiology, and a more comprehensive diagnostic stroke workup than in unselected cohorts (8.95% vs 4.51%). Pooled AF detection rates rose with monitoring duration: 3.5% (1 day), 6.3% (7 days), 9.6% (30 days), 13.1% (90 days), 19.1% (12 months). Implantable cardiac monitors yielded a significantly higher AF detection rate than non-invasive cardiac monitoring (i.e., serial ECGs, 24-72h Holter, in-hospital telemetry) (20.8% vs. 4.7%). Substantial heterogeneity was observed among studies (I2 = 81.9%). Conclusions This meta-analysis including several studies with prolonged and invasive ECG monitoring found a high detection rate of AF in TIA patients. Randomized studies comparing the impact of different ECG monitoring methods on clinical endpoints are needed in TIA patients. Conflict of interest Alexander W Veltkamp: nothing to disclose. Eleni Korompoki: Speaker Honoraria/Advisory boards/Travel grants: Amgen, AstraZeneca, Bayer, Elpen, Innovis, Pfizer, Sanofi. Lucio D'Anna: nothing to disclose. Manuel C Olma: nothing to disclose. Karl Georg Haeusler: Speaker´s honoraria, consulting fees, lecture honoraria and/or study grants from Abbott, Amarin; Alexion, AstraZeneca, Bayer Healthcare, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Medtronic, Novartis, Pfizer, Portola, Premier Research, Sanofi, SUN Pharma, and W.L. Gore and Associates. Matthias Endres: funding from DFG under Germany´s Excellence Strategy – EXC-2049 – 390688087 , Collaborative Research Center ReTune TRR 295- 424778381, Clinical Research Group KFO 5023 BeCAUSE-Y, project 2 EN343/16-1, Research Group FOR 5930 AbsInVasc, project 6 EN343/18-1, BMBF, DZNE, DZHK, DZPG, and EU; grants from Bayer and Ipsen, and fees paid to the Charité from Amgen, AstraZeneca, Bayer Healthcare, BMS, Daiichi Sankyo, all outside the submitted work. Roland Veltkamp: research support from European Union’s Horizon 2020 research and innovation program under grant agreement No 754517, and from Bayer, BMS-Pfizer, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Biogen. Honoraria for consultancies and lectures for Astra Zeneca, Bayer, BMS-Pfizer, Javelin, Portola, and he is an investigator of the Imperial BRC.